Advice

Following a full submission.

Tipranavir (Aptivus) in combination with low dose ritonavir is not recommended for use within NHS Scotland for the treatment of HIV-1 infection in highly pre-treated adult patients with virus resistant to multiple protease inhibitors.

At 48 weeks, tipranavir, in combination with low dose ritonavir, showed a significant improvement in the reduction of viral load compared with other protease inhibitor plus ritonavir regimens. Although the overall rate and type of adverse events were similar, tipranavir had a higher incidence of hepatotoxicity, hyperlipidaemia, bleeding events and rash.

Tipranavir is more expensive than other protease inhibitors and the economic case for its use has not been demonstrated

Download detailed advice46KB (PDF)

Download

Medicine details

Medicine name:
Tipranavir (Aptivus®)
SMC ID:
226/05
Indication:
HIV
Pharmaceutical company
Boehringer Ingelheim Ltd
BNF chapter
Infections
Submission type
Full
Status
Not recommended
Date advice published:
09 January 2006